HUP0302847A2 - Bikalutamidot tartalmazó gyógyászati készítmény - Google Patents

Bikalutamidot tartalmazó gyógyászati készítmény

Info

Publication number
HUP0302847A2
HUP0302847A2 HU0302847A HUP0302847A HUP0302847A2 HU P0302847 A2 HUP0302847 A2 HU P0302847A2 HU 0302847 A HU0302847 A HU 0302847A HU P0302847 A HUP0302847 A HU P0302847A HU P0302847 A2 HUP0302847 A2 HU P0302847A2
Authority
HU
Hungary
Prior art keywords
cellulose acetate
trimellitate
hydroxypropyl
phthalate
cellulose
Prior art date
Application number
HU0302847A
Other languages
English (en)
Inventor
Nicola Bateman
Julie Cahill
Original Assignee
Astrazeneca Ab,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0104749A external-priority patent/GB2372444A/en
Priority claimed from SE0102572A external-priority patent/SE0102572D0/xx
Application filed by Astrazeneca Ab, filed Critical Astrazeneca Ab,
Publication of HUP0302847A2 publication Critical patent/HUP0302847A2/hu
Publication of HUP0302847A3 publication Critical patent/HUP0302847A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya gyógyászati készítmény mukozális adagolásra, ami(I) képletű bikalutamidot tartalmaz 3 és 6 közötti pKa értékű bélbenoldódó polimerrel képezett szilárd diszperzió formájában. A készítménybélben oldódó polimerként előnyösen hidroxi-propil-metil-cellulóz-acetát-szukcinátot (HPMCAS), hidroxi-propil-metil-cellulóz-acetát-ftalátot; hidroxi-propil-metil-cellulóz-acetátot, hidroxi-propil-metil-cellulóz-szukcinátot, metakrilsav kopolimereket, poli(vinil-acetát-ftalát)-ot (PVAP), cellulóz-acetát-ftalátot (CAP), metil-cellulóz-acetát-ftalátot, etil-cellulóz-acetát-ftalátot, hidroxi-propil-cellulóz-acetát-ftalátot, hidroxi-propil-metil-cellulóz-ftalátot (HPMCP), cellulóz-propionát-ftalátot, hidroxi-propil-cellulóz-butirát-ftalátot, hidroxi-propil-cellulóz-acetát-ftalát-szukcinátot, hidroxi-propil-metil-cellulóz-trimellitátot, cellulóz-acetát-trimellitátot (CAT), metil-cellulóz-acetát-trimellitátot, etil-cellulóz-acetát-trimellitátot, hidroxi-propil-cellulóz-acetát-trimellitátot, hidroxi-propil-metil-cellulóz-acetát-trimellitátot,hidroxi-propil-cellulóz-acetát-trimellitát-szukcinátot, cellulóz-propionát-trimellitátot, cellulóz-butirát-trimellitátot, cellulóz-acetát-tereftalátot és/vagy cellulóz-acetát-izoftalátot tartalmazhat. Ó
HU0302847A 2001-02-27 2002-02-22 Pharmaceutical formulation comprising bicalutamide HUP0302847A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0104749A GB2372444A (en) 2001-02-27 2001-02-27 A pharmaceutical formulation comprising bicalutamide and a hydroxypropylmethylcellulose polymer
SE0102572A SE0102572D0 (sv) 2001-07-19 2001-07-19 Pharmaceutical formulation
PCT/GB2002/000766 WO2002067893A2 (en) 2001-02-27 2002-02-22 Pharmaceutical formulation comprising bicalutamide

Publications (2)

Publication Number Publication Date
HUP0302847A2 true HUP0302847A2 (hu) 2003-12-29
HUP0302847A3 HUP0302847A3 (en) 2005-05-30

Family

ID=26245766

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302847A HUP0302847A3 (en) 2001-02-27 2002-02-22 Pharmaceutical formulation comprising bicalutamide

Country Status (22)

Country Link
US (1) US20040067257A1 (hu)
EP (1) EP1368001B1 (hu)
JP (2) JP3548566B2 (hu)
KR (1) KR20030077042A (hu)
CN (1) CN1503662A (hu)
AR (1) AR032912A1 (hu)
AT (1) ATE307571T1 (hu)
CA (1) CA2439366A1 (hu)
CZ (1) CZ20032225A3 (hu)
DE (1) DE60206889T2 (hu)
EE (1) EE200300416A (hu)
HU (1) HUP0302847A3 (hu)
IL (1) IL157389A0 (hu)
IS (1) IS6915A (hu)
MX (1) MXPA03007641A (hu)
NO (1) NO20033785L (hu)
NZ (1) NZ527532A (hu)
PL (1) PL365746A1 (hu)
RU (1) RU2003128971A (hu)
SK (1) SK10722003A3 (hu)
UY (1) UY27186A1 (hu)
WO (1) WO2002067893A2 (hu)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
WO2005074991A1 (ja) * 2004-02-09 2005-08-18 Kabushiki Kaisha Sangi 抗腫瘍剤
KR100539706B1 (ko) * 2005-01-25 2005-12-28 지엘팜텍 주식회사 타크로리무스 및 장용성 고분자를 함유하는 고체분산체
JP2008531531A (ja) * 2005-02-23 2008-08-14 アストラゼネカ アクチボラグ 方法
JP5097540B2 (ja) * 2005-04-06 2012-12-12 株式会社サンギ 腸管吸収用抗腫瘍剤
US7785629B2 (en) * 2005-06-21 2010-08-31 Helm Ag Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JPWO2009038112A1 (ja) 2007-09-21 2011-01-06 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
JP5204452B2 (ja) * 2007-10-02 2013-06-05 日医工株式会社 ビカルタミド含有製剤
EP2219624A2 (en) * 2007-11-08 2010-08-25 Glaxo Group Limited Pharmaceutical formulations
CN105237530A (zh) 2009-04-03 2016-01-13 豪夫迈罗氏公司 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途
CN101987086B (zh) * 2009-08-03 2012-07-18 北京化工大学 一种超细比卡鲁胺口服片剂及其制备方法
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011057022A1 (en) 2009-11-06 2011-05-12 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
JP6109574B2 (ja) 2009-12-18 2017-04-05 カタラン、フランス、バインハイム、ソシエテ、アノニムＣａｔａｌｅｎｔ Ｆｒａｎｃｅ Ｂｅｉｎｈｅｉｍ Ｓａ 合成オリゴサッカリドを含有する医薬経口剤形
CN102525876B (zh) * 2010-12-15 2014-03-12 西安力邦医药科技有限责任公司 阿司匹林固体分散体、其制备方法、药物组合物和用途
CN102552103B (zh) * 2010-12-20 2013-11-20 西安力邦医药科技有限责任公司 拉米夫定固体分散体、其制备方法、药物组合物和用途
PT2672967T (pt) 2011-02-07 2018-12-07 Plexxikon Inc Compostos e métodos de modulação da quinase e suas indicações
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN109897004A (zh) 2012-09-11 2019-06-18 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
JP2017523206A (ja) * 2014-08-07 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の新規製剤
EP3226843B1 (en) 2014-12-05 2021-05-26 Aragon Pharmaceuticals, Inc. Anticancer compositions
CN109646404B (zh) * 2016-12-15 2022-10-04 华领医药技术（上海）有限公司 葡萄糖激酶激活剂的口服制剂及其制备方法
CA3134550A1 (en) 2019-04-11 2020-10-15 R.P. Scherer Technologies, Llc Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
GB2584341B (en) 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
AU1537292A (en) * 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
EP0748220A4 (en) * 1994-01-21 1997-09-10 Sepracor Inc METHOD AND COMPOSITIONS FOR TREATING ANDROGEN-DEPENDENT DISEASES USING OPTICALLY PURE R - (-) CASODEX
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
ATE324886T1 (de) * 2001-04-02 2006-06-15 Astrazeneca Ab Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103839D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product

Also Published As

Publication number Publication date
CZ20032225A3 (cs) 2003-11-12
EP1368001B1 (en) 2005-10-26
CA2439366A1 (en) 2002-09-06
IL157389A0 (en) 2004-05-12
EP1368001A2 (en) 2003-12-10
NO20033785L (no) 2003-10-24
NO20033785D0 (no) 2003-08-26
SK10722003A3 (sk) 2004-02-03
DE60206889T2 (de) 2006-07-27
NZ527532A (en) 2004-12-24
IS6915A (is) 2003-08-15
JP3548566B2 (ja) 2004-07-28
JP2004143185A (ja) 2004-05-20
ATE307571T1 (de) 2005-11-15
DE60206889D1 (de) 2005-12-01
WO2002067893A3 (en) 2003-01-16
HUP0302847A3 (en) 2005-05-30
AR032912A1 (es) 2003-12-03
EE200300416A (et) 2003-12-15
KR20030077042A (ko) 2003-09-29
MXPA03007641A (es) 2003-12-04
CN1503662A (zh) 2004-06-09
JP2004521918A (ja) 2004-07-22
UY27186A1 (es) 2002-09-30
PL365746A1 (en) 2005-01-10
WO2002067893A2 (en) 2002-09-06
RU2003128971A (ru) 2005-03-10
US20040067257A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
HUP0302847A2 (hu) Bikalutamidot tartalmazó gyógyászati készítmény
TR199800902T2 (xx) Ecza form�lasyonlar�.
AU7207098A (en) Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations
NO20060786L (no) Farmasoytiske preparater med oppsvulmbart belegg
DE60039377D1 (de) Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
KR920702618A (ko) 약제학적 제형
CO5271674A1 (es) Particulas farmaceuticas con enmascaramiento de sabor
NO993519L (no) Fenofibrat farmasöytisk blanding som har höy biotilgjengelighet og fremgangsmÕte for fremstilling av den
HUP0201711A2 (en) Indanyl-substituted benzole carbonamide, method for the production of the same, use thereof as a medicament and pharmaceutical preparations containing the same
DE60100866D1 (de) Cyklosporin, Hyaluronsäure und Polysorbate enthaltenes Augenarzneimittel
AR020610A1 (es) Utilizacion de un copolimero de acido metacrilico de tipo c segun la farmacopea us national formulary usp/nf, como agente de desagregacion y el procedimiento de fabricaion de un comprimido con dicho copolimero
DK1121144T3 (da) Stabile koncentrerede insulinpræparater til pulmonar indgivelse
CY1106159T1 (el) Φαρμακευτικη συνθεση που πepιλαμβανει πενιχρα υδατοδιαλυτη σταυροσπορινη, επιφανειοδραστικη ουσια και υδατοδιαλυτο πολυμepες
BR0109943A (pt) Composições farmacêuticas
CO5601038A2 (es) Formulacion farmaceutica de iressa que comprende un derivado de celulosa hidrosoluble
CO4910139A1 (es) Formulaciones en particulas revestidas
FI971533A0 (fi) Lyofilisoituja farmaseuttisia valmisteita, jotka kykenevät muodostamaan vesipitoisen lääkekoostumuksen, jolla on palautuvan, lämpökovettuvan geelittymisen ominaisuus
UY27474A1 (es) Formulación de dosificación oral de fusion instantanea.
PT1355635E (pt) Novo revestimento de pelicula
WO2001070288A3 (en) Thermoreversible polymers for delivery and retention of osteoinductive proteins
EP2502998A3 (en) Recombinant toxin A/ToxinB vaccine against clostridium difficile
WO2005039481A3 (en) Oral drug delivery system
AU777185C (en) Pharmaceutical form of administration for peptides, methods for its production and use
CO5580755A2 (es) Formulacion farmaceutica comprendiendo (r)-bicalutamida
AU4943000A (en) Taste masked compositions

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees